STOCK TITAN

[Form 4] Nuvalent, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Nuvalent, Inc. (NUVL) filed a Form 4 disclosing that director Christy J. Oliger received new equity awards on 18 June 2025.

  • 3,971 Restricted Stock Units (RSUs): Granted at no cost. The RSUs convert to an equal number of Class A shares in three equal annual installments beginning one year from the grant date, provided the director remains in service.
  • 6,119 Stock Options: Right to buy Class A shares at an exercise price of $75.53, expiring 18 June 2035. Vesting occurs monthly over the three-year period following the grant.

Post-grant, Oliger directly owns 3,971 Class A shares and holds derivative rights (options) to acquire an additional 6,119 shares. The filing reports no sales or dispositions.

These awards form part of Nuvalent’s standard director compensation package, creating long-term alignment with shareholder interests through multi-year vesting schedules. Because the transactions are grants rather than market purchases or sales, they do not immediately affect cash flow or trading volume but do incrementally increase potential dilution if options are exercised in the future.

Nuvalent, Inc. (NUVL) ha presentato un Modulo 4 comunicando che la direttrice Christy J. Oliger ha ricevuto nuove assegnazioni di azioni il 18 giugno 2025.

  • 3.971 Unità di Azioni Vincolate (RSU): Concesse senza alcun costo. Le RSU si trasformano in un numero equivalente di azioni di Classe A in tre rate annuali uguali a partire da un anno dalla data di assegnazione, a condizione che la direttrice rimanga in carica.
  • 6.119 Opzioni su Azioni: Diritto di acquistare azioni di Classe A al prezzo di esercizio di 75,53 $, con scadenza il 18 giugno 2035. Il vesting avviene mensilmente nel corso dei tre anni successivi all’assegnazione.

Dopo l’assegnazione, Oliger detiene direttamente 3.971 azioni di Classe A e possiede diritti derivati (opzioni) per acquisirne ulteriori 6.119. La dichiarazione segnala nessuna vendita o cessione.

Questi premi fanno parte del pacchetto standard di compensi per i direttori di Nuvalent, creando un allineamento a lungo termine con gli interessi degli azionisti tramite programmi di vesting pluriennali. Poiché le transazioni sono assegnazioni e non acquisti o vendite di mercato, non influenzano immediatamente il flusso di cassa o il volume di scambio, ma aumentano progressivamente la potenziale diluizione se le opzioni verranno esercitate in futuro.

Nuvalent, Inc. (NUVL) presentó un Formulario 4 informando que la directora Christy J. Oliger recibió nuevas concesiones de acciones el 18 de junio de 2025.

  • 3,971 Unidades de Acciones Restringidas (RSUs): Otorgadas sin costo. Las RSUs se convierten en un número igual de acciones Clase A en tres cuotas anuales iguales a partir de un año desde la fecha de concesión, siempre que la directora continúe en servicio.
  • 6,119 Opciones sobre Acciones: Derecho a comprar acciones Clase A a un precio de ejercicio de $75.53, con vencimiento el 18 de junio de 2035. La adquisición de derechos se realiza mensualmente durante los tres años posteriores a la concesión.

Tras la concesión, Oliger posee directamente 3,971 acciones Clase A y mantiene derechos derivados (opciones) para adquirir otras 6,119. El informe indica ninguna venta o disposición.

Estas concesiones forman parte del paquete estándar de compensación para directores de Nuvalent, generando una alineación a largo plazo con los intereses de los accionistas mediante planes de adquisición de derechos plurianuales. Dado que las transacciones son concesiones y no compras o ventas en el mercado, no afectan inmediatamente el flujo de efectivo ni el volumen de negociación, pero aumentan gradualmente la posible dilución si las opciones se ejercen en el futuro.

Nuvalent, Inc. (NUVL)은 2025년 6월 18일 이사 Christy J. Oliger가 신규 주식 보상 수여를 받았음을 공개하는 Form 4를 제출했습니다.

  • 3,971 제한 주식 단위(RSU): 비용 없이 부여됨. RSU는 부여일로부터 1년 후부터 3년에 걸쳐 매년 동일한 수량의 클래스 A 주식으로 전환되며, 이사가 계속 근무하는 경우에 한합니다.
  • 6,119 주식 매수선택권: 행사 가격 $75.53에 클래스 A 주식을 매수할 권리로, 2035년 6월 18일 만료됩니다. 권리 취득은 부여 후 3년 동안 매월 이루어집니다.

부여 후 Oliger는 직접 3,971 클래스 A 주식을 보유하고 있으며, 추가로 6,119 주식을 취득할 수 있는 파생 권리(옵션)를 보유하고 있습니다. 제출 서류에는 판매 또는 처분이 없었다고 보고되어 있습니다.

이 보상은 Nuvalent의 표준 이사 보상 패키지의 일부로, 다년간의 권리 취득 일정으로 주주 이익과 장기적으로 일치하도록 설계되었습니다. 거래가 시장 매수나 매도가 아닌 부여 형태이므로 즉각적인 현금 흐름이나 거래량에 영향은 없으나, 향후 옵션 행사 시 잠재적 희석 효과가 점진적으로 증가합니다.

Nuvalent, Inc. (NUVL) a déposé un formulaire 4 révélant que la directrice Christy J. Oliger a reçu de nouvelles attributions d’actions le 18 juin 2025.

  • 3 971 unités d’actions restreintes (RSU) : Octroyées sans frais. Les RSU se convertissent en un nombre égal d’actions de Classe A en trois versements annuels égaux à partir d’un an après la date d’attribution, à condition que la directrice reste en fonction.
  • 6 119 options d’achat d’actions : Droit d’acheter des actions de Classe A au prix d’exercice de 75,53 $, expirant le 18 juin 2035. L’acquisition des droits s’effectue mensuellement sur une période de trois ans suivant l’attribution.

Après l’attribution, Oliger possède directement 3 971 actions de Classe A et détient des droits dérivés (options) pour acquérir 6 119 actions supplémentaires. Le dépôt indique aucune vente ou cession.

Ces attributions font partie du package de rémunération standard des administrateurs de Nuvalent, créant un alignement à long terme avec les intérêts des actionnaires grâce à des calendriers d’acquisition pluriannuels. Étant donné que les transactions sont des attributions et non des achats ou ventes sur le marché, elles n’affectent pas immédiatement les flux de trésorerie ou le volume des échanges, mais augmentent progressivement la dilution potentielle si les options sont exercées à l’avenir.

Nuvalent, Inc. (NUVL) hat ein Formular 4 eingereicht, in dem offengelegt wird, dass die Direktorin Christy J. Oliger am 18. Juni 2025 neue Aktienzuteilungen erhalten hat.

  • 3.971 Restricted Stock Units (RSUs): Unentgeltlich gewährt. Die RSUs wandeln sich in eine gleiche Anzahl von Class A Aktien in drei gleichen jährlichen Raten um, beginnend ein Jahr nach dem Zuteilungsdatum, vorausgesetzt, die Direktorin bleibt im Dienst.
  • 6.119 Aktienoptionen: Recht, Class A Aktien zum Ausübungspreis von 75,53 $ zu kaufen, mit Ablaufdatum 18. Juni 2035. Die Vesting erfolgt monatlich über den Zeitraum von drei Jahren nach der Zuteilung.

Nach der Zuteilung besitzt Oliger direkt 3.971 Class A Aktien und hält derivative Rechte (Optionen) zum Erwerb weiterer 6.119 Aktien. Die Meldung berichtet keine Verkäufe oder Veräußerungen.

Diese Zuteilungen sind Teil des standardmäßigen Vergütungspakets für Direktoren von Nuvalent und schaffen eine langfristige Ausrichtung an den Interessen der Aktionäre durch mehrjährige Vesting-Pläne. Da es sich um Zuteilungen und nicht um Markttransaktionen handelt, beeinflussen sie nicht unmittelbar den Cashflow oder das Handelsvolumen, erhöhen jedoch potenziell die Verwässerung, falls die Optionen in Zukunft ausgeübt werden.

Positive
  • No insider selling: All reported transactions are grants, suggesting alignment rather than profit-taking.
  • Long-term vesting: Three-year schedules incentivize sustained performance and director retention.
Negative
  • None.

Insights

TL;DR: Routine director equity grants; signals alignment, limited immediate market impact.

The Form 4 details typical board-level compensation: time-based RSUs and options with a strike ($75.53) near recent trading levels. No cash outlay or share sale occurred, so the filing has neutral short-term impact on supply-demand dynamics. The size—≈10k potential shares—represents a fraction of Nuvalent’s float and therefore minimal dilution risk. The three-year vesting and 10-year option term encourage long-term oversight but do not alter the investment thesis or financial outlook.

TL;DR: Standard equity incentive enhances board alignment; governance posture unchanged.

Multi-year RSU and option grants are common for biotech boards. Monthly option vesting promotes continuous engagement, while annual RSU vesting offers retention leverage. The absence of performance conditions is typical for director pay but means value is tied to share price alone. Overall, the structure is shareholder-friendly, yet not materially different from prevailing practices, leaving governance quality and risk profile intact.

Nuvalent, Inc. (NUVL) ha presentato un Modulo 4 comunicando che la direttrice Christy J. Oliger ha ricevuto nuove assegnazioni di azioni il 18 giugno 2025.

  • 3.971 Unità di Azioni Vincolate (RSU): Concesse senza alcun costo. Le RSU si trasformano in un numero equivalente di azioni di Classe A in tre rate annuali uguali a partire da un anno dalla data di assegnazione, a condizione che la direttrice rimanga in carica.
  • 6.119 Opzioni su Azioni: Diritto di acquistare azioni di Classe A al prezzo di esercizio di 75,53 $, con scadenza il 18 giugno 2035. Il vesting avviene mensilmente nel corso dei tre anni successivi all’assegnazione.

Dopo l’assegnazione, Oliger detiene direttamente 3.971 azioni di Classe A e possiede diritti derivati (opzioni) per acquisirne ulteriori 6.119. La dichiarazione segnala nessuna vendita o cessione.

Questi premi fanno parte del pacchetto standard di compensi per i direttori di Nuvalent, creando un allineamento a lungo termine con gli interessi degli azionisti tramite programmi di vesting pluriennali. Poiché le transazioni sono assegnazioni e non acquisti o vendite di mercato, non influenzano immediatamente il flusso di cassa o il volume di scambio, ma aumentano progressivamente la potenziale diluizione se le opzioni verranno esercitate in futuro.

Nuvalent, Inc. (NUVL) presentó un Formulario 4 informando que la directora Christy J. Oliger recibió nuevas concesiones de acciones el 18 de junio de 2025.

  • 3,971 Unidades de Acciones Restringidas (RSUs): Otorgadas sin costo. Las RSUs se convierten en un número igual de acciones Clase A en tres cuotas anuales iguales a partir de un año desde la fecha de concesión, siempre que la directora continúe en servicio.
  • 6,119 Opciones sobre Acciones: Derecho a comprar acciones Clase A a un precio de ejercicio de $75.53, con vencimiento el 18 de junio de 2035. La adquisición de derechos se realiza mensualmente durante los tres años posteriores a la concesión.

Tras la concesión, Oliger posee directamente 3,971 acciones Clase A y mantiene derechos derivados (opciones) para adquirir otras 6,119. El informe indica ninguna venta o disposición.

Estas concesiones forman parte del paquete estándar de compensación para directores de Nuvalent, generando una alineación a largo plazo con los intereses de los accionistas mediante planes de adquisición de derechos plurianuales. Dado que las transacciones son concesiones y no compras o ventas en el mercado, no afectan inmediatamente el flujo de efectivo ni el volumen de negociación, pero aumentan gradualmente la posible dilución si las opciones se ejercen en el futuro.

Nuvalent, Inc. (NUVL)은 2025년 6월 18일 이사 Christy J. Oliger가 신규 주식 보상 수여를 받았음을 공개하는 Form 4를 제출했습니다.

  • 3,971 제한 주식 단위(RSU): 비용 없이 부여됨. RSU는 부여일로부터 1년 후부터 3년에 걸쳐 매년 동일한 수량의 클래스 A 주식으로 전환되며, 이사가 계속 근무하는 경우에 한합니다.
  • 6,119 주식 매수선택권: 행사 가격 $75.53에 클래스 A 주식을 매수할 권리로, 2035년 6월 18일 만료됩니다. 권리 취득은 부여 후 3년 동안 매월 이루어집니다.

부여 후 Oliger는 직접 3,971 클래스 A 주식을 보유하고 있으며, 추가로 6,119 주식을 취득할 수 있는 파생 권리(옵션)를 보유하고 있습니다. 제출 서류에는 판매 또는 처분이 없었다고 보고되어 있습니다.

이 보상은 Nuvalent의 표준 이사 보상 패키지의 일부로, 다년간의 권리 취득 일정으로 주주 이익과 장기적으로 일치하도록 설계되었습니다. 거래가 시장 매수나 매도가 아닌 부여 형태이므로 즉각적인 현금 흐름이나 거래량에 영향은 없으나, 향후 옵션 행사 시 잠재적 희석 효과가 점진적으로 증가합니다.

Nuvalent, Inc. (NUVL) a déposé un formulaire 4 révélant que la directrice Christy J. Oliger a reçu de nouvelles attributions d’actions le 18 juin 2025.

  • 3 971 unités d’actions restreintes (RSU) : Octroyées sans frais. Les RSU se convertissent en un nombre égal d’actions de Classe A en trois versements annuels égaux à partir d’un an après la date d’attribution, à condition que la directrice reste en fonction.
  • 6 119 options d’achat d’actions : Droit d’acheter des actions de Classe A au prix d’exercice de 75,53 $, expirant le 18 juin 2035. L’acquisition des droits s’effectue mensuellement sur une période de trois ans suivant l’attribution.

Après l’attribution, Oliger possède directement 3 971 actions de Classe A et détient des droits dérivés (options) pour acquérir 6 119 actions supplémentaires. Le dépôt indique aucune vente ou cession.

Ces attributions font partie du package de rémunération standard des administrateurs de Nuvalent, créant un alignement à long terme avec les intérêts des actionnaires grâce à des calendriers d’acquisition pluriannuels. Étant donné que les transactions sont des attributions et non des achats ou ventes sur le marché, elles n’affectent pas immédiatement les flux de trésorerie ou le volume des échanges, mais augmentent progressivement la dilution potentielle si les options sont exercées à l’avenir.

Nuvalent, Inc. (NUVL) hat ein Formular 4 eingereicht, in dem offengelegt wird, dass die Direktorin Christy J. Oliger am 18. Juni 2025 neue Aktienzuteilungen erhalten hat.

  • 3.971 Restricted Stock Units (RSUs): Unentgeltlich gewährt. Die RSUs wandeln sich in eine gleiche Anzahl von Class A Aktien in drei gleichen jährlichen Raten um, beginnend ein Jahr nach dem Zuteilungsdatum, vorausgesetzt, die Direktorin bleibt im Dienst.
  • 6.119 Aktienoptionen: Recht, Class A Aktien zum Ausübungspreis von 75,53 $ zu kaufen, mit Ablaufdatum 18. Juni 2035. Die Vesting erfolgt monatlich über den Zeitraum von drei Jahren nach der Zuteilung.

Nach der Zuteilung besitzt Oliger direkt 3.971 Class A Aktien und hält derivative Rechte (Optionen) zum Erwerb weiterer 6.119 Aktien. Die Meldung berichtet keine Verkäufe oder Veräußerungen.

Diese Zuteilungen sind Teil des standardmäßigen Vergütungspakets für Direktoren von Nuvalent und schaffen eine langfristige Ausrichtung an den Interessen der Aktionäre durch mehrjährige Vesting-Pläne. Da es sich um Zuteilungen und nicht um Markttransaktionen handelt, beeinflussen sie nicht unmittelbar den Cashflow oder das Handelsvolumen, erhöhen jedoch potenziell die Verwässerung, falls die Optionen in Zukunft ausgeübt werden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Oliger Christy J.

(Last) (First) (Middle)
C/O NUVALENT, INC.
ONE BROADWAY, 14TH FLOOR

(Street)
CAMBRIDGE MA 02142

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Nuvalent, Inc. [ NUVL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 06/18/2025 A 3,971(1) A $0.00 3,971 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $75.53 06/18/2025 A 6,119 (2) 06/18/2035 Class A Common Stock 6,119 $0.00 6,119 D
Explanation of Responses:
1. Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in three equal annual installments following June 18, 2025, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
2. The shares underlying this option vest over the three years following June 18, 2025, in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
/s/ Nathan N. McConarty, attorney-in-fact 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity did NUVL director Christy Oliger receive on 18 June 2025?

She was granted 3,971 RSUs and options for 6,119 shares of Class A stock.

What is the exercise price of the new NUVL stock options?

The options carry an exercise price of $75.53 per share.

When will the 3,971 RSUs granted to the NUVL director vest?

They vest in three equal annual installments starting one year after 18 Jun 2025.

Did the Form 4 report any sale of Nuvalent shares by the director?

No. The filing shows only equity grants, with zero shares sold or disposed of.

What is the expiration date of the newly granted NUVL stock options?

The options expire on 18 June 2035.
Nuvalent, Inc.

NASDAQ:NUVL

NUVL Rankings

NUVL Latest News

NUVL Latest SEC Filings

NUVL Stock Data

5.66B
62.83M
2.9%
108.09%
7.75%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE